GlassScriptPhysician profile
Sanjeev Rastogi
NPI 1326044702
$871.45
in general payments reported to CMS, 2019-2025
15 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2021: $220 · 2022: $72.08 · 2023: $32.76 · 2024: $81.79 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $205 · Education: $29.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $205.45 |
| Education | $29.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $323.86 | 2019-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $113.39 | 2019 | |
| Janssen Pharmaceuticals, INC | $78.49 | 2019 | |
| Travere Therapeutics, INC. | $64.53 | 2022-2024 | |
| Amgen INC. | $53.93 | 2019-2025 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $43.41 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $40.03 | 2022-2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $33.94 | 2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $33.87 | 2019 | |
| Vifor Pharma, INC. | $23.57 | 2022 | |
| Opko Pharmaceuticals, LLC | $16.73 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2019 | |
| Fresenius USA Marketing, INC. | $14.63 | 2019 | |
| Glaxosmithkline, LLC. | $14.51 | 2023 | Benlysta |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjeev Rastogi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.